Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer

Background: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with r...

Full description

Bibliographic Details
Main Authors: Yoshie Nakayama, Yoshinori Ito, Masahiko Tanabe, Shunji Takahashi
Format: Article
Language:English
Published: Karger Publishers 2013-01-01
Series:Case Reports in Oncology
Subjects:
Online Access:http://www.karger.com/Article/FullText/346839
_version_ 1819017135311028224
author Yoshie Nakayama
Yoshinori Ito
Masahiko Tanabe
Shunji Takahashi
author_facet Yoshie Nakayama
Yoshinori Ito
Masahiko Tanabe
Shunji Takahashi
author_sort Yoshie Nakayama
collection DOAJ
description Background: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with recurrent breast cancer was treated with bevacizumab and paclitaxel. Positron emission tomography revealed breast cancer metastasis to the left supraclavicular lymph nodes and right axillary lymph nodes, with no distant metastasis. Results: After the third cycle of bevacizumab and paclitaxel, the patient developed a bloody bowel discharge. Emergent colonoscopy demonstrated diverticular bleeding on one of the multiple diverticula in the ascending colon. The bleeding point was successfully clipped colonoscopically. Conclusion: The factors for diverticular bleeding are believed to be non-steroidal anti-inflammatory drugs, constipation, and bevacizumab. We recommend reviewing anamneses for diverticulitis, multiple prior abdominal surgeries, peritoneal carcinomatosis, and regular use of certain drugs.
first_indexed 2024-12-21T02:58:43Z
format Article
id doaj.art-773b6e3da848427f8cba96ebbbe8897e
institution Directory Open Access Journal
issn 1662-6575
language English
last_indexed 2024-12-21T02:58:43Z
publishDate 2013-01-01
publisher Karger Publishers
record_format Article
series Case Reports in Oncology
spelling doaj.art-773b6e3da848427f8cba96ebbbe8897e2022-12-21T19:18:14ZengKarger PublishersCase Reports in Oncology1662-65752013-01-0161505410.1159/000346839346839Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast CancerYoshie NakayamaYoshinori ItoMasahiko TanabeShunji TakahashiBackground: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with recurrent breast cancer was treated with bevacizumab and paclitaxel. Positron emission tomography revealed breast cancer metastasis to the left supraclavicular lymph nodes and right axillary lymph nodes, with no distant metastasis. Results: After the third cycle of bevacizumab and paclitaxel, the patient developed a bloody bowel discharge. Emergent colonoscopy demonstrated diverticular bleeding on one of the multiple diverticula in the ascending colon. The bleeding point was successfully clipped colonoscopically. Conclusion: The factors for diverticular bleeding are believed to be non-steroidal anti-inflammatory drugs, constipation, and bevacizumab. We recommend reviewing anamneses for diverticulitis, multiple prior abdominal surgeries, peritoneal carcinomatosis, and regular use of certain drugs.http://www.karger.com/Article/FullText/346839Opioid analgesicsBreast cancerBevacizumabPaclitaxelAdverse effectsDiverticular bleedingNon-steroidal anti-inflammatory drugs
spellingShingle Yoshie Nakayama
Yoshinori Ito
Masahiko Tanabe
Shunji Takahashi
Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
Case Reports in Oncology
Opioid analgesics
Breast cancer
Bevacizumab
Paclitaxel
Adverse effects
Diverticular bleeding
Non-steroidal anti-inflammatory drugs
title Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
title_full Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
title_fullStr Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
title_full_unstemmed Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
title_short Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
title_sort diverticular bleeding of the colon during combination chemotherapy with bevacizumab and paclitaxel for recurrent breast cancer
topic Opioid analgesics
Breast cancer
Bevacizumab
Paclitaxel
Adverse effects
Diverticular bleeding
Non-steroidal anti-inflammatory drugs
url http://www.karger.com/Article/FullText/346839
work_keys_str_mv AT yoshienakayama diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer
AT yoshinoriito diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer
AT masahikotanabe diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer
AT shunjitakahashi diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer